NCT02445976 2019-02-01
Once-daily Oral Seviteronel in Patients With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone.
Innocrin Pharmaceutical
Phase 2 Completed
Clinical Trials
3 trialsNCT02580448 2019-02-01
CLARITY-01
Innocrin Pharmaceutical
Phase 1/2 Completed
NCT02130700 2018-05-07
Oral VT-464 in Patients With Castration-Resistant Prostate Cancer Previously Treated With Enzalutamide, Androgen Receptor Positive Triple-Negative Breast Cancer Patients, and Men With ER Positive Breast Cancer
Innocrin Pharmaceutical
Phase 2 Completed